Your browser doesn't support javascript.
loading
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
Genovese, Mark C; Braun, Daniel K; Erickson, Janelle S; Berclaz, Pierre-Yves; Banerjee, Subhashis; Heffernan, Michael P; Carlier, Hilde.
Afiliação
  • Genovese MC; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Braun DK; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Erickson JS; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Berclaz PY; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Banerjee S; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Heffernan MP; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
  • Carlier H; From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and
J Rheumatol ; 43(2): 289-97, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26669919
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Rheumatol Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Rheumatol Ano de publicação: 2016 Tipo de documento: Article